B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma

Neoplasia

Volumn 13, Issue 10, 2011, Pages 947-960

  Candolfi, Marianela ^a,b   Curtin, James F ^a,b   Yagiz, Kader ^a,b   Assi, Hikmat ^a,b   Wibowo, Mia K ^a,b   Alzadeh, Gabrielle E ^a,b   Foulad, David ^a,b   Muhammad, Akm G ^a,b   Salehi, Sofia ^a,b   Keech, Naomi ^a,b   Puntel, Mariana ^a,b   Liu, Chunyan ^a,b   Sanderson, Nicholas R ^a,b   Kroeger, Kurt M ^a,b   Dunn, Robert ^c   Martins, Gislaine ^a,b   Lowenstein, Pedro R ^a,b   Castro, Maria G ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD135 ANTIGEN; CYTOTOXIC AGENT; THYMIDINE KINASE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; MOUSE; NONHUMAN; PRE T LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT FAILURE; TUMOR IMMUNITY; TUMOR REGRESSION; WILD TYPE;

EID: 80054793682     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11024     Document Type: Article

References (65)

1. Heimberger AB and Sampson JH (2011). Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol 13, 3-13.
2. Curtin J, Liu N, Candolfi M, Xiong W, Assi A, Yagiz K, Edwards M, Michelsen K, Kroeger K, Liu C, et al. (2009). HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 6, e10.
3. Chien PY, Wang J, Carbonaro D, Lei S, Miller B, Sheikh S, Ali SM, Ahmad MU, and Ahmad I (2005). Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 12, 321-328.
4. GhulamMuhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, Kroeger KM, Treuer KA, Nichols WS, Sanderson NS, et al. (2009). Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 15, 6113-6127.
5. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, and Risberg B (2006). NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 125, 451-458.
6. Nzula S, Going JJ, and Stott DI (2003). Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 63, 3275-3280.
7. Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, and Glassy MC (2005). Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol 175, 2278-2285.
8. de Visser KE, Korets LV, and Coussens LM (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423.
9. Rodriguez-Pinto D (2005). B cells as antigen presenting cells. Cell Immunol 238, 67-75.
10. Inoue S, Leitner WW, Golding B, and Scott D (2006). Inhibitory effects of B cells on antitumor immunity. Cancer Res 66, 7741-7747.
11. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH, et al. (2005). Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 117, 574-586.
12. Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, and Kaplan JM (2004). Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 27, 273-281.
13. Li Q, Grover AC, Donald EJ, Carr A, Yu J, Whitfield J, Nelson M, Takeshita N, and Chang AE (2005). Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells. J Immunol 175, 1424-1432.
14. Pillai S, Cariappa A, and Moran ST (2005). Marginal zone B cells. Annu Rev Immunol 23, 161-196.
15. Cinamon G, Zachariah MA, Lam OM, Foss FW Jr, and Cyster JG (2008). Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 9, 54-62.
16. Lopes-Carvalho T, Foote J, and Kearney JF (2005). Marginal zone B cells in lymphocyte activation and regulation. Curr Opin Immunol 17, 244-250.
17. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, and Tisch RM (1998). B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 161, 3912-3918.
18. Chan OT, Hannum LG, Haberman AM, Madaio MP, and Shlomchik MJ (1999). A novel mouse with B cells but lacking serum antibody reveals an antibodyindependent role for B cells in murine lupus. J Exp Med 189, 1639-1648.
19. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, and Weyand CM (2001). T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167, 4710-4718.
20. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, and Hwu P (2003). CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63, 2836-2843.
21. von Bergwelt-Baildon M, Schultze JL, Maecker B, Menezes I, and Nadler LM (2004). Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43.
22. Cancer Res 64, 4055-4056; author reply 4056-4057.
23. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, and Nadler LM (1997). CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigenspecific T cells for adoptive immunotherapy. J Clin Invest 100, 2757-2765.
24. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, and Calame K (2003). Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 19, 607-620.
25. Yang J, Sanderson NSR, Wawrowsky K, Puntel M, Castro MG, and Lowenstein PR (2010). Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo. Proc Natl Acad Sci USA 107, 4716-4721.
26. Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, and Bigner DD (1997). Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41, 1365-1372; discussion 1372-1363.
27. Yu S, Dunn R, Kehry MR, and Braley-Mullen H (2008). B cell depletion inhibits spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J Immunol 180, 7706-7713.
28. Lu TT and Cyster JG (2002). Integrin-mediated long-term B cell retention in the splenic marginal zone. Science 297, 409-412.
29. Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, Puntel M, Kroeger KM, Liu C, Lee S, et al. (2009). Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 15, 4401-4414.
30. Robertson JM, Jensen PE, and Evavold BD (2000). DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J Immunol 164, 4706-4712.
31. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, and Heimberger AB (2006). The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8, 261-279.
32. Ngo VN, Cornall RJ, and Cyster JG (2001). Splenic T zone development is B cell dependent. J Exp Med 194, 1649-1660.
33. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, Kelsoe G, and Tedder TF (2008). Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180, 361-371.
34. Belperron AA, Dailey CM, Booth CJ, and Bockenstedt LK (2007). Marginal zone B-cell depletion impairs murine host defense against Borrelia burgdorferi infection. Infect Immun 75, 3354-3360.
35. Ray RJ, Paige CJ, Furlonger C, Lyman SD, and Rottapel R (1996). Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur J Immunol 26, 1504-1510.
36. Buza-Vidas N, Cheng M, Duarte S, Nozad H, Jacobsen SE, and Sitnicka E (2007). Crucial role of FLT3 ligand in immune reconstitution after bone marrow transplantation and high-dose chemotherapy. Blood 110, 424-432.
37. Carrasco YR and Batista FD (2007). B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 27, 160-171.
38. Okada T, Miller MJ, Parker I, Krummel MF, Neighbors M, Hartley SB, O'Garra A, Cahalan MD, and Cyster JG (2005). Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 3, e150.
39. Hon H, Oran A, Brocker T, and Jacob J (2005). B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol 174, 5233-5242.
40. Hoft DF, Eickhoff CS, Giddings OK, Vasconcelos JR, and Rodrigues MM (2007). Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J Immunol 179, 6889-6900.
41. Clark MR, Massenburg D, Siemasko K, Hou P, and Zhang M (2004). B-cell antigen receptor signaling requirements for targeting antigen to the MHC class II presentation pathway. Curr Opin Immunol 16, 382-387.
42. Evans DE, Munks MW, Purkerson JM, and Parker DC (2000). Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40. J Immunol 164, 688-697.
43. Croft M (1994). Activation of naive, memory and effector T cells. Curr Opin Immunol 6, 431-437.
44. Kim S, Fridlender ZG, Dunn R, Kehry MR, Kapoor V, Blouin A, Kaiser LR, and Albelda SM (2008). B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother 31, 446-457.
45. Gadri Z, Kukulansky T, Bar-Or E, Haimovich J, and Hollander N (2009). Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma. J Immunother 32, 333-340.
46. Vasilevko V, Xu F, Previti ML, Van Nostrand WE, and Cribbs DH (2007). Experimental investigation of antibody-mediated clearance mechanisms of amyloid-ß in CNS of Tg-SwDI transgenic mice. J Neurosci 27, 13376-13383.
47. Ankeny DP and Popovich PG (2011). B cells and autoantibodies: complex roles in CNS injury. Trends Immunol 31, 332-338.
48. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, et al. (2001). Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24, 363-373.
49. Knutson KL, Schiffman K, Cheever MA, and Disis ML (2002). Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8, 1014-1018.
50. Crawford A, Macleod M, Schumacher T, Corlett L, and Gray D (2006). Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 176, 3498-3506.
51. Brigl M and Brenner MB (2004). CD1: antigen presentation and T cell function. Annu Rev Immunol 22, 817-890.
52. Diaz-de-Durana Y, Mantchev GT, Bram RJ, and Franco A (2006). TACI-BLyS signaling via B-cell-dendritic cell cooperation is required for naive CD8+ T-cell priming in vivo. Blood 107, 594-601.
53. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, and Moser M (2000). B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 192, 475-482.
54. Wykes M, Pombo A, Jenkins C, and MacPherson GG (1998). Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol 161, 1313-1319.
55. Wykes M and MacPherson G (2000). Dendritic cell-B-cell interaction: dendritic cells provide B cells with CD40-independent proliferation signals and CD40- dependent survival signals. Immunology 100, 1-3.
56. Constant S, Schweitzer N, West J, Ranney P, and Bottomly K (1995). B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol 155, 3734-3741.
57. Attanavanich K and Kearney JF (2004). Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J Immunol 172, 803-811.
58. Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, and Bechmann I (2006). T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol 80, 797-801.
59. Gonzalez SF, Degn SE, Pitcher LA, Woodruff M, Heesters BA, and Carroll MC (2011). Trafficking of B cell antigen in lymph nodes. Annu Rev Immunol 29, 215-233.
60. Lindell DM, Berlin AA, Schaller MA, and Lukacs NW (2008). B cell antigen presentation promotes TH2 responses and immunopathology during chronic allergic lung disease. PLoS One 3, e3129.
61. Stock AT, Mueller SN, van Lint AL, Heath WR, and Carbone FR (2004). Cutting edge: prolonged antigen presentation after herpes simplex virus-1 skin infection. J Immunol 173, 2241-2244.
62. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, Lew AM, Shortman K, Heath WR, and Carbone FR (2006). Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25, 153-162.
63. Cumberbatch M and Kimber I (1995). Tumour necrosis factor-a is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology 84, 31-35.
64. Coughlin CM, Vance BA, Grupp SA, and Vonderheide RH (2004). RNAtransfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103, 2046-2054.
65. Jiang W, Lederman MM, Harding CV, and Sieg SF (2011). Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells. J Immunol 186, 2080-2086.